直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • News
  • Finnegan Facts
  • History
    • Finnegan VISION
    • Finnegan FORWARD
  • Pro Bono
  • Management
    • Pricing & Alternative Fee Arrangements
    • AFA Models We Offer
    • Contingency Fees
    • AI + KM

James R. Barney

Actavis Agrees to Hold Off on Generic Version of Nuvigil

March 22, 2011

Law360

Cephalon Inc. has dropped their patent infringement suit against Actavis Inc. over a generic version of Nuvigil®, a drug for narcolepsy. The decision came after Actavis made the decision not to produce a competing version of the drug, which treats sleep apnea and shift work sleep disorder in addition to narcolepsy. Cephalon is represented by Finnegan.

Related News

Press Release

Finnegan Secures Summary Determination of No Violation in ITC Vehicle Space Guards Investigation for Drop Stop

October 6, 2026

Commentary

Federal Circuit Revives Whistleblower Complaint Over VA's AI Claims-Processing Tool

September 25, 2026

Award/Ranking

Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026

September 23, 2026

Commentary

New Thomas Pink Womenswear Lines Strain ‘Pink’ Pact with Victoria’s Secret

September 21, 2026

Commentary

Jellycat’s ‘Dupe’ Dilemma: Can IP Protect a ‘Cute’ Aesthetic?

September 16, 2026

Commentary

Uncrustables Fame Ruling Sets Up Functionality Fight Over Crimped Edge

September 11, 2026

Award/Ranking

Finnegan Wins “Hatch-Waxman Litigation Firm of the Year – Branded” and David Weingarten Wins “Patent Strategy Attorney of the Year (South)” at the LMG Life Sciences Americas Awards

September 11, 2026

Media Mention

Finnegan Opens First Texas Office with ‘Two Leaders with Genuine Local Roots'

September 7, 2026

Commentary

Finnegan Joins Growing Wave of Firms Moving into Texas

September 4, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP